Sodium-glucose cotransporter-2 inhibitors in cancer patients with type 2 diabetes and established immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis - Takeaways - MDSpire

Sodium-glucose cotransporter-2 inhibitors in cancer patients with type 2 diabetes and established immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis

  • By

  • Ling Guo

  • Jing Liu

  • Ruipu Gao

  • Chunwang Yang

  • Zhenli Li

  • Zhengkun Guan

  • Yansong Wang

  • Guang Liu

  • Jingtao Ma

  • Guangbin Gao

  • April 15, 2026

  • 0 min

Share

  • 1

    SGLT2i use in cancer patients with T2DM and iRCs was associated with significantly reduced all-cause mortality.

  • 2

    Patients using SGLT2i had a longer median survival time compared to those not using SGLT2i.

  • 3

    The SGLT2i group exhibited a lower proportion of high-grade iRCs compared to the non-SGLT2i group.

  • 4

    No significant difference in MACE incidence was found between SGLT2i and non-SGLT2i groups, but trends favored SGLT2i.

  • 5

    The study highlights the need for prospective validation of SGLT2i's cardioprotective and potential oncologic benefits.

Original Source(s)

Sodium-glucose cotransporter-2 inhibitors in cancer patients with type 2 diabetes and established immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis

  • by Ling Guo, Jing Liu, Ruipu Gao, Chunwang Yang, Zhenli Li, Zhengkun Guan, Yansong Wang, Guang Liu, Jingtao Ma, Guangbin Gao

  • April 15, 2026

Related Content

Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination

Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies

Case Report: Clinical case of a giant plexiform neurofibroma of the liver in a patient with deletion of exon 1 of the NF1 gene